Labcorp (LH)
(Delayed Data from NYSE)
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
LabCorp (LH) Stock Moves -0.57%: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $276.30, moving -0.57% from the previous trading session.
Analysts Estimate LabCorp (LH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $271.14 in the latest trading session, marking a +1.5% move from the prior day.
LabCorp (LH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $264.88, moving +0.24% from the previous trading session.
LabCorp (LH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $263.66, moving -1.99% from the previous trading session.
LabCorp (LH) Gains From Covance Arm Growth, Cost Pressure Ails
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development arm is benefiting from its collaborations with leading pharmaceutical and biotechnology companies.
LabCorp (LH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $273.96, moving +0.93% from the previous trading session.
LabCorp (LH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, LabCorp (LH) closed at $271.44, marking a -0.09% move from the previous day.
Should Value Investors Consider LabCorp (LH) Stock Now?
by Zacks Equity Research
Let's see if LabCorp (LH) stock is a good choice for value-oriented investors right now from multiple angles.
LabCorp (LH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, LabCorp (LH) closed at $274.33, marking a +0.11% move from the previous day.
LabCorp (LH) Stock Moves -0.27%: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $265.49 in the latest trading session, marking a -0.27% move from the prior day.
Here's Why You Should Hold on to LabCorp (LH) Stock For Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) better-than-expected results and robust base business performance.
Walgreens (WBA) Expands Access to COVID-19 Test With LabCorp
by Zacks Equity Research
Walgreens (WBA) will enable more communities to access reliable, convenient testing services as and when required with the addition of Pixel by LabCorp COVID-19 at-home collection kit.
Is John Hancock Multifactor Mid Cap ETF (JHMM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JHMM
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHMM
LabCorp (LH) Expands Clinical Laboratory Services With New Pact
by Zacks Equity Research
LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.
LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
LabCorp (LH) reports better-than-expected results for the fourth quarter, with solid contributions from the Drug Development business driving the top line.
LabCorp (LH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 14.75% and 2.95%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q4 Earnings on Feb 10: BIO, DXCM & LH
by Urmimala Biswas
Medical device companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BIO, DXCM, and LH are poised ahead of their earnings releases.
Why Earnings Season Could Be Great for Laboratory Corporation (LH)
by Zacks Equity Research
Laboratory Corporation (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cerner (CERN) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
Doximity (DOCS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Doximity's (DOCS) fiscal third-quarter results are likely to reflect growth in its telehealth platform and robust net revenue retention rate.
Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) Q4 top line.
LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.